Necrotizing Fasciitis Treatment Market is Growing Dynamically Increasing at a CAGR of 6.2% During Forecast to 2023

Necrotizing Fasciitis Market – Insights

The Global Necrotizing Fasciitis Market is expected to grow at a CAGR of 6.2% during the forecasted period.

The Global Necrotizing Fasciitis Treatment Market Trends is expecting a steady growth during the forecasted period. Necrotizing fasciitis is a bacterial infection that affects tissue beneath the skin, surrounding muscles, and organs. Growing geriatric population, increasing prevalence of infectious diseases and technological advancement in surgery has driven the market growth. Moreover, increasing healthcare expenditure, and rising demand for the better treatment has fueled the growth of the market. However, lack of awareness about the disease in developing economies and poor reimbursement policies in developed countries may slow the growth of this market. 

Necrotizing Fasciitis Market - Key Players

·         Merck & Co. (U.S.)

·         WOCKHARDT (India)

·         Atox Bio (Israel)

·         Teva Pharmaceutical Industries (Israel)

·         Basilea Pharmaceutica Ltd. (Switzerland)

·         MELINTA THERAPEUTICS, INC. (U.S.)

Necrotizing Fasciitis Market - Segmentation

·         The Global Necrotizing Fasciitis Market is segmented on the basis of pathogen, types, treatment, and end users.

·         On the basis of the type, the market is categorized into Type I, Type II, Type III and others.

·         On the basis of the treatment, the market is segmented into intravenous antibiotics, surgery, hyperbaric oxygen treatment, and others.

·         On the basis of the end users, the market is segmented into hospitals & clinics, surgical centers, and others.

Necrotizing Fasciitis Market - Regional Analysis

The Americas dominate the global Necrotizing Fasciitis Market owing to the presence of population suffering from bacterial infection and increasing number of surgical procedures in the hospitals. America is further segmented into North America and South America. North America holds the largest market owing to extensive use of advanced technology and developed pharmaceutical sector.

Europe accounts for the second largest market due to increasing funds, government support and increasing healthcare expenditure. Germany, France, and the U.K hold a significant share in the market owing to increasing demand of technologically advanced devices for the surgical procedures and overall growth of medical device industry.

Asia Pacific is the fastest growing market for the necrotizing fasciitis, whose growth is attributed to rising geriatric population, increasing prevalence of people suffering from bacterial infections and rapidly developing economies. Additionally, increasing healthcare expenditure and demand for new treatment options for rare diseases fuel the market growth. India and China are the major contributors to the market growth due to the rapid development of healthcare sector in these regions and increasing demand for diagnostic services.

On the other hand, the Middle East & Africa is expected witness limited growth due to limited access to the healthcare resources and lack of awareness about rare diseases. In the Middle East, the growth of the Necrotizing Fasciitis Market is driven by increasing availability new diagnostic and treatment methods for various chronic and acute bacterial infections.